Tango Therapeutics (TNGX) was granted FDA orphan designation for its treatment of malignant glioma, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- 3 Strong Buy-Rated Stocks with a ‘Perfect 10’ Smart Score
- Tango Therapeutics’ Chief Legal Officer Resigns
- Palo Alto upgraded, Li Auto downgraded: Wall Street’s top analyst calls
- Piper starts Tango Therapeutics with an Overweight on TNG462 potential
- Tango Therapeutics initiated with an Overweight at Piper Sandler